Independent Academic Research Groups

ARQ National Psychotrauma Centre is a leading Dutch institute specializing in the treatment and research of complex psychotrauma and PTSD, with roots in addressing the psychological wounds of World War II since 1945 and now one of Europe's foremost psychotrauma centers. ARQ is one of nine European sites conducting MAPS-affiliated clinical trials of MDMA-assisted therapy for PTSD, and integrates medication-assisted approaches including MDMA and ketamine into its high-intensity trauma treatment programs in partnership with Leiden University Medical Center.

AZ Delta is a major Belgian hospital group headquartered in Roeselare, Flanders, operating four campuses with 1,403 approved beds. It participates in the multi-centre BIKe (Brain Injury and Ketamine) randomized controlled trial (NCT05097261) investigating ketamine's safety as an adjunct sedative in severe traumatic brain injury.

AZ Sint-Jan Brugge-Oostende AV is a leading Belgian teaching hospital in Bruges with a dedicated Clinical Trial Center (CTC) that sponsors and participates in academic and commercial drug studies. Its Department of Anesthesiology and Intensive Care Medicine is a confirmed site in the BIKe (Brain Injury and Ketamine) randomized controlled trial (NCT05097261) investigating ketamine's role in severe traumatic brain injury management.

AZ Turnhout is a general hospital in Turnhout, Antwerp province, Belgium, providing comprehensive medical and surgical care to the northern Campine region. Its Department of Anesthesiology and Intensive Care Medicine is a confirmed site in the BIKe (Brain Injury and Ketamine) randomized controlled trial (NCT05097261) investigating ketamine as an adjunct sedative in severe traumatic brain injury patients.

Dr. Anna Rose Childress is a Research Associate Professor of Psychology in Psychiatry at the University of Pennsylvania Perelman School of Medicine and Director of the Brain-Behavioral Vulnerabilities Laboratory at the Center for Studies of Addiction, with over four decades of NIDA-funded research on brain reward circuits and craving in substance use disorders. She is now advancing into psilocybin research, contributing to Penn's clinical trial of psilocybin for opioid use disorder and publicly addressing regional barriers to psychedelic-assisted therapy.

Assistance Publique – Hôpitaux de Paris (AP-HP) is France's largest public hospital system, comprising 39 hospitals including Pitié-Salpêtrière and Sainte-Anne, and serving as Europe's leading academic medical center complex with extensive clinical research infrastructure. AP-HP institutions actively contribute to psychedelic medicine research, including participation in COMPASS Pathways' Phase 3 psilocybin trials for treatment-resistant depression and ketamine studies through the Paris Brain Institute.

Assistance Publique Hôpitaux de Marseille (AP-HM) is the public hospital authority of Marseille, France, comprising four major hospital groups and operating as one of the largest university hospital centers in Europe with extensive clinical research infrastructure. AP-HM has been involved in psychedelic medicine research through its clinical trial network, contributing to France's emerging landscape of psychiatry trials exploring psychedelic-assisted therapies.

Assiut University is a major public university in Upper Egypt whose Faculty of Medicine Department of Neurology and Psychiatry has contributed to ketamine research in treatment-resistant depression. The department conducted a double-blind randomized controlled trial of ketamine for TRD with psychiatric comorbidities, published in the Journal of Affective Disorders, establishing Assiut as a participant in the broader clinical research landscape relevant to psychedelic medicine.

AstraZeneca is a British-Swedish multinational biopharmaceutical company developing medicines across oncology, cardiovascular, respiratory, and neurological areas, with psychiatric products that intersect with psychedelic research contexts. AstraZeneca's antidepressants and psychiatric medications have featured as active comparators in landmark psychedelic clinical trials, including the influential psilocybin vs. escitalopram depression study at Imperial College London.

Academic medical center in Houston affiliated with multiple Texas Medical Center hospitals. Conducts psilocybin and MDMA clinical trials for veteran PTSD in partnership with the Michael E. DeBakey VA, and houses the ELIPSIS program — a dedicated initiative on the ethical and legal implications of psychedelics in society.

Bayside Health, operating as Alfred Health, is a Melbourne-based public healthcare network comprising The Alfred, Caulfield Hospital, and Sandringham Hospital, and serves as the principal teaching hospital partner for Monash University's Clinical Psychedelic Lab. As host institution for Victoria's major trauma and psychiatric services, it provides clinical infrastructure supporting Australia's psychedelic therapy programmes following the 2023 TGA rescheduling.

Fundación Beckley Med is a Barcelona-based psychedelic research and education organisation, partnered with the UK's Beckley Foundation, that funds and disseminates psychedelic-assisted therapy studies and provides professional training through institutional affiliations with MAPS, Grof Legacy, and CIIS. It collaborated with CITA Clinic to deliver experimental ketamine treatment to patients with treatment-resistant depression in Spain.

Israeli psychiatric hospital near Tel Aviv that served as a key clinical trial site for MAPS-sponsored MDMA-assisted psychotherapy for PTSD, with Dr. Moshe Kotler serving as principal investigator. Beer Yaakov is slated to participate in future MAPS Israel trials treating post-October 7 PTSD among Nova festival survivors and soldiers, in collaboration with the Israeli Ministry of Health.

China's premier neurology and neurosurgery hospital, affiliated with Capital Medical University and home to the National Clinical Research Center for Neurological Diseases. Conducted the PASSION trial — a randomized, placebo-controlled study of intraoperative ketamine for depression in neurosurgical patients.

Benha University is a public Egyptian university whose Faculty of Medicine and Psychiatry Department has contributed to research on ketamine and esketamine for treatment-resistant depression within the Egyptian academic and clinical context. As a key medical institution in the Nile Delta region, it participates in collaborative psychiatric research networks exploring novel pharmacological treatments for mood disorders.

UC Berkeley Center for the Science of Psychedelics (BCSP), founded in September 2020 by a multidisciplinary faculty group including neuroscientist Michael Silver and author Michael Pollan, conducting psilocybin research into cognition, perception, emotion, and their neural bases in the human brain. BCSP's four pillars of basic science, journalism, culture, and community have established it as a leading interdisciplinary hub for psychedelic research and public engagement, producing The Microdose newsletter and a global clinical trials map.

Berry Consultants is a US statistical consulting firm specializing in Bayesian adaptive clinical trial design, with expertise in platform trials and adaptive dose-finding studies increasingly applied in psychedelic and psychiatric drug development. The firm has engaged with regulatory frameworks for psychedelic medicines, including commenting on FDA guidance for clinical trials involving psilocybin and MDMA.

Bispebjerg Hospital is a major Copenhagen university hospital and the coordinating site for PsyPal, the EU-funded multi-centre trial investigating psilocybin-assisted therapy for anxiety and existential distress in patients with ALS—the first European publicly-funded psychedelic trial of its kind. Affiliated with the University of Copenhagen, the hospital leads Nordic clinical research into psychedelic-assisted therapies for neurological and palliative conditions.

Braxia Scientific Corp. (CSE: BRAX) is a Canadian publicly-listed medical research company that operates a network of ketamine and psilocybin treatment clinics across Ontario and Quebec through its subsidiary Canadian Rapid Treatment Centre of Excellence, and conducted Canada's first multi-dose Phase II psilocybin randomized controlled trial for treatment-resistant depression. The company received Health Canada Special Access Program approval to deliver psilocybin-assisted therapy in Ontario and holds government-funded grants for ketamine trials in bipolar depression, led by researchers Dr. Roger McIntyre and Dr. Joshua Rosenblat.

Major academic medical center in Boston affiliated with Harvard Medical School and part of the Mass General Brigham health system. Researchers at BWH are active in the emerging field of psychedelic-assisted therapy, including psilocybin studies for gastrointestinal conditions and ethical frameworks for psychedelic pain research.

The James J. Peters VA Medical Center (Bronx VA) in New York is home to the Center for Psychedelic Psychotherapy and Trauma Research—a joint initiative with Mount Sinai's Icahn School of Medicine led by Dr. Rachel Yehuda—which pioneered the first FDA-approved randomized MDMA-assisted psychotherapy trial within the VA system and has conducted ketamine-based trials for chronic PTSD and suicidal ideation in veterans. The center is one of nine VA facilities participating in the expanded national VA psychedelic-assisted therapy research program.

The Bronx Veterans Medical Research Foundation (BVMRF) is a 501(c)(3) nonprofit that administers extramural research funding for the James J. Peters VA Medical Center and VA Hudson Valley Health Care System, supporting mental health, biomedical, and rehabilitation research focused on veteran populations. In the psychedelic context, it provides the administrative research infrastructure supporting MDMA-assisted therapy for PTSD and ketamine studies conducted at the Bronx VA's Center for Psychedelic Psychotherapy and Trauma Research.

Brooke Army Medical Center (BAMC) at Joint Base San Antonio is the US Army's flagship medical institution and the Department of Defense's only Level I Trauma Center, and has been a primary site in multi-center randomized controlled trials investigating ketamine for antidepressant-resistant PTSD in active duty military and veterans. BAMC researchers have also contributed to pilot studies on service members' perspectives on psychedelic-assisted therapies including MDMA and psilocybin for PTSD and traumatic brain injury.

Bruyère Health Research Institute is the academic research arm of Bruyère Health in Ottawa, Canada, fully affiliated with the University of Ottawa and specializing in palliative care, aging, and rehabilitation research—areas with growing overlap with psychedelic-assisted therapy applications. The institute contributed to a major Ontario population study examining schizophrenia risk following hallucinogen-related emergency department visits, generating safety evidence informing screening protocols for psychedelic clinical trials.

CH TAC LLC (Cluster Headache-Trigeminal Autonomic Cephalalgia, LLC) is a US non-profit research entity that co-sponsored Yale University's Phase 1 psilocybin trials for episodic and chronic cluster headache, in partnership with Heffter Research Institute and Ceruvia Lifesciences.

CHU de Québec–Université Laval is Quebec City's largest university hospital network, affiliated with Université Laval and serving as a major clinical research hub. It hosts the P3A Study Group led by Dr. Michel Dorval (Oncology Division), conducting a psilocybin-assisted psychotherapy trial for existential distress in patients with advanced cancer.

Columbia University Irving Medical Center (CUIMC) is a major academic medical centre in New York City, integrating Columbia University's Vagelos College of Physicians and Surgeons with NewYork-Presbyterian Hospital and conducting research across neuroscience, psychiatry, and translational medicine. CUIMC serves as the primary clinical site for the Ketamine Biomarker Validation trial (NCT07307768), an EEG-based Phase I study examining dose-response relationships across three ketamine infusion levels in adults with treatment-resistant major depressive disorder.

The California Pacific Medical Center Research Institute (CPMCRI) is the academic research arm of California Pacific Medical Center in San Francisco, whose physician-scientists have contributed to the Bay Area’s psychedelic research ecosystem through advisory roles at the CIIS Center for Psychedelic Therapies and Research and collaborative ties to MAPS for evaluating MDMA-assisted therapy. CPMCRI conducts translational and clinical research across oncology, neurology, and psychiatry in partnership with UCSF and other Bay Area institutions.

Cambridge Cognition (AIM: COG) is a UK-based cognitive technology company that develops and licenses the CANTAB neuropsychological assessment platform, validated in over 3,000 publications and widely adopted in psychedelic clinical trials—including psilocybin and MDMA studies—to objectively measure cognitive outcomes at baseline, during, and after treatment. CANTAB’s digital cognitive assessments have become a de facto standard endpoint tool in psychiatric drug development, supporting the field’s progression through Phase 2 and Phase 3 psychedelic trials.

Canisius-Wilhelmina Hospital (CWZ) is a major teaching hospital in Nijmegen, Netherlands, whose Department of Neurology has contributed to psychedelic research including an evidence-based review of LSD and psilocybin for chronic pain management, examining serotonin-2A receptor-mediated neuroplastic mechanisms. Situated in the Netherlands—one of Europe’s most active countries for psychedelic research—CWZ participates in neurological research exploring psychedelic compounds as therapeutic agents for pain and psychiatric conditions.

The Center for Medicinal Cannabis Research (CMCR) is a California state-funded research program at UC San Diego that rigorously evaluates the medical efficacy and safety of cannabis and cannabinoids through placebo-controlled clinical trials, with regulatory expertise in Schedule I research that overlaps with psychedelic medicine. CMCR has been cited in psychedelic trial contexts for its methodological framework and experience navigating DEA/FDA processes for controlled-substance clinical research applicable to psilocybin and MDMA studies.

The Central Institute of Mental Health (ZI Mannheim) is a leading German psychiatric research institute affiliated with Heidelberg University, and under Prof. Dr. Gerhard Gründer is one of Europe’s foremost centers for psychedelic research—co-leading EPIsoDE, Germany’s first federal government-funded (BMBF, €2.2M) Phase II RCT of psilocybin for treatment-resistant depression, and receiving one of the first compassionate-use approvals for psilocybin in Germany and the EU, with results published in Lancet Psychiatry in 2025. The institute also conducts molecular neuroimaging research on MDMA and psilocybin mechanisms, and has reported successful ketamine treatment outcomes in treatment-resistant depression.

GHU Paris Psychiatrie et Neurosciences (the current form of historic Hôpital Sainte-Anne) is France's leading university psychiatric hospital, pioneering psychedelic research under Jean Delay from the 1930s and now leading a 2024 ANR-funded psilocybin RCT aimed at dissociating therapeutic effects from acute psychedelic experience in treatment-resistant depression.

University hospital in Charleroi, Belgium affiliated with the Université Libre de Bruxelles. Participates in clinical trials for psychiatric and neurological conditions, including studies in the emerging area of esketamine and rapid-acting antidepressant therapies.

The Centre for Human Drug Research (CHDR) in Leiden, Netherlands is a world-class early-phase clinical research organization conducting approximately 60 trials per year, with a specialist psychiatry department that has become one of Europe’s leading sites for psychedelic compound research—including psilocybin, DMT, MDMA, and ketamine—using advanced tools such as the NeuroCart CNS battery and EEG to quantify pharmacodynamic endpoints. CHDR has conducted first-in-human studies with novel non-hallucinogenic neuroplastogens and intravenous DMT regimens, establishing it as a key early-phase partner for psychedelic drug development.

The Centre for Neurology Studies (CNS) is a private clinical research centre in Surrey, British Columbia, and one of Canada’s few dedicated neuroscience-focused clinical trial organizations, conducting Health Canada and FDA-approved studies in mental health, neurodegenerative disorders, and brain health. Operating within British Columbia’s growing clinical trials ecosystem, CNS has participated in research on novel psychiatric treatments relevant to the emerging psychedelic medicine field.

The Centre hospitalier de l’Université de Montréal (CHUM) is one of Canada’s leading academic health centres and home to psychiatrist Dr. Nicolas Garel, co-developer of the ‘Montreal Model’—a ketamine-assisted psychotherapy protocol for severe treatment-resistant depression that integrates psychedelic-inspired non-pharmacological adjuncts with structured psychiatric care. The MUSIK trial, conducted at CHUM and published in the British Journal of Psychiatry, demonstrated sustained 8-week depression relief and established that ketamine’s mystical experiences are central to its antidepressant mechanism.

Cessatech A/S is a Copenhagen-based paediatric biotech developing CT001, a first-in-class intranasal ketamine/sufentanil combination analgesic for acute pain in children aged 1–17, with an EMA Marketing Authorisation Application submitted in 2025 and approval expected in 2026.

Charité – Universitätsmedizin Berlin is Europe’s largest university hospital and a co-lead site of the BMBF-funded EPIsoDE Phase IIb psilocybin trial for treatment-resistant depression; its Psychedelic Substances Research Group under Prof. Tomislav Majć also investigates MDMA for PTSD and ketamine for depression.

Dr. Charles S. Grob is Professor of Psychiatry at Harbor-UCLA Medical Center and a founding figure of modern psychedelic medicine, having conducted the first FDA-approved MDMA study in 1994 and the first modern psilocybin trial for cancer-related existential anxiety, and co-leading an ongoing multisite psilocybin palliative care trial with UCSF.

The Children’s Hospital of Eastern Ontario (CHEO) is a leading Canadian pediatric tertiary care hospital in Ottawa affiliated with the University of Ottawa; CHEO Research Institute supports over 250 researchers, and CHEO is conducting a clinical trial of IV ketamine for suicidal ideation in youth.

The Children’s Hospital of Fudan University (CHFU) is China’s top-ranked pediatric hospital, affiliated with Fudan University Shanghai Medical College, and is a trial site for esketamine-based therapies in rare pediatric neurological conditions including a clinical study of esketamine for Rett syndrome.

Children's National Research Institute is the research enterprise of Children's National Hospital in Washington, D.C., conducting translational and clinical research across pediatric disciplines. It is a site in the KESETT trial (Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial), investigating ketamine as an adjunctive therapy for refractory pediatric status epilepticus.

China Medical University (中国医科大学), based in Shenyang, Liaoning, is a leading Chinese medical institution conducting research on ketamine and esketamine for treatment-resistant depression and other psychiatric conditions. Its affiliated hospitals and departments participate in multi-centre esketamine trials and publish meta-analyses on ketamine's antidepressant mechanisms.

The Copenhagen Trial Unit (CTU), Centre for Clinical Intervention Research, is a non-specialty clinical research unit at Rigshospitalet (Copenhagen University Hospital), supporting rigorous randomised clinical trials and systematic reviews across all medical disciplines since 2000. Located at the same hospital campus as the Neurobiology Research Unit conducting active psilocybin neuroimaging studies, CTU provides the trial methodology, statistical expertise, and conduct infrastructure that enables clinical psychedelic research in Denmark.

Cy Biopharma AG is a Swiss biotech company developing novel psilocybin-derived small molecule therapies for chronic pain and other CNS conditions, with a focus on rare and orphan indications. Operating from Baar, Switzerland, Cy screens biochemical extracts combined with serotonin receptor agonists to create new molecular entities, and has formed a strategic supply and collaboration partnership with Australian life sciences company Bioxyne Limited for Australasia and global markets.

CZECRIN (Czech Clinical Research Infrastructure Network) is the Czech national node of the pan-European ECRIN-ERIC research infrastructure, supporting non-commercial academic clinical trials across Czech hospitals and research institutions. It has actively showcased the PSIKET001 and PSIKET002 trials — landmark double-blind comparisons of psilocybin versus ketamine for treatment-resistant depression at the National Institute of Mental Health — as flagship examples of Czech psychedelic clinical innovation.

The Department of Psychiatry at UPK Basel (Universitäre Psychiatrische Kliniken Basel), led by Professor Stefan Borgwardt, is a leading academic centre for psychedelic neuroscience and clinical pharmacology. Borgwardt's group has conducted multiple placebo-controlled neuroimaging and pharmacokinetic trials with LSD, psilocybin, and MDMA, generating foundational findings on thalamic connectivity and hallucinogenic mechanisms that underpin contemporary psychedelic-assisted psychiatry.

ERT (rebranded as Clario in 2021 following a merger with Bioclinica) is a clinical trial technology company providing eCOA/ePRO electronic outcome assessment platforms, cardiac safety, and respiratory services for drug development, including FDA-validated psychiatric rating scale libraries and eC-SSRS suicide-ideation monitoring used in psychedelic and ketamine trials. The company has supported over 3,500 clinical trials and underpinned more than 60% of 2017 FDA treatment approvals.

Ehave Inc. is a Canadian digital health company providing telemetry and data-collection platforms for precision-medicine clinical trials, including psychedelic and ketamine research; their KetaDASH product enables ketamine home-delivery monitoring for medical practitioners. The company holds an FDA-authorized IND for a ketamine EEG study in major depressive disorder.

EmpathBio Inc. is an ATAI Life Sciences subsidiary developing EMP-01, an MDMA derivative designed to preserve entactogenic therapeutic properties while reducing cardiovascular and stimulant side effects, with PTSD as the primary indication. The company completed a Phase 1 trial of EMP-01 in 32 healthy volunteers in New Zealand.

Empower Research Inc. is the corporate research entity behind Empower Psychedelics, running Health Canada-approved trials on psychedelic-assisted group therapy for first responders in partnership with MAPS Canada. The organization has also studied medically perceived benefits of psychedelics and cannabinoids among first responders and military personnel.

The European Association for Palliative Care (EAPC) is the leading European professional body for palliative care research, education, and policy, headquartered in Milan. The EAPC is a core consortium partner in PsyPal, the first EU-funded multi-site psilocybin clinical trial (€6.5M), studying psilocybin-assisted therapy for psychological distress in patients with COPD, MS, ALS, and atypical Parkinson's disease across multiple European sites.

The Federal University for Latin American Integration (UNILA) is a bilingual public university at the Foz do Iguaçu tri-national border between Brazil, Argentina, and Paraguay, focused on regional integration sciences. UNILA's clinical neuropharmacology laboratory, led by Francisney Nascimento, is conducting ayahuasca trials for prolonged grief disorder and developing a randomized placebo-controlled psilocybin clinical trial.

Field Trip Health was a Canadian publicly traded ketamine-assisted psychotherapy company founded in 2019 that operated clinics across North America and Europe while developing FT-104, a shorter-duration psilocybin analog, before a 2023 financial restructuring under Canada's Companies' Creditors Arrangement Act. Its drug development assets were spun off as Reunion Neuroscience (which raised $103M Series A in 2024) while its US clinic network was acquired by Stella and its Canadian clinics by the Canadian Centre for Psychedelic Healing.

The First Affiliated Hospital of Chongqing Medical University is a major academic teaching hospital in Chongqing, China, that has been a prolific clinical site for ketamine and esketamine research, with multiple randomized controlled trials spanning postpartum depression prevention, major depressive disorder combined with electroconvulsive therapy, and depression following miscarriage. Its departments of psychiatry and anesthesiology have published landmark studies demonstrating esketamine's efficacy across multiple psychiatric indications.

Miami public research university where Dr. Jerry B. Brown has taught interdisciplinary psychedelics courses since 1975, and Professor Joseph Lichter runs an Honors College Psychedelic Renaissance course covering therapeutic applications of psilocybin, MDMA, and ketamine. FIU also serves as one of 21 sites in a major national psychedelic clinical trial and hosts the Cannadelic conference — the first cannabis and psychedelics conference focused on next-generation research.

Vrije Universiteit Amsterdam (VU Amsterdam) is a major Dutch research university where neuroscientist Marco Aqil conducted the first psilocybin brain research in Amsterdam, demonstrating that psilocybin fundamentally alters visual processing by reducing cortical surround suppression. The university also hosts the Amsterdam Psychedelic Research Association (APRA) and offers an interdisciplinary honors course on the neuroscience, history, and therapeutic potential of psychedelics.

One of Europe's foremost centres for psychedelic-assisted therapy, operating within Switzerland's compassionate use framework. Under Professor Daniele Zullino, HUG treats depression and PTSD with psilocybin, LSD, and MDMA, and hosts one of five university-affiliated psychedelic research laboratories in Switzerland.

Hospital Universitari Germans Trias i Pujol is a major public academic hospital in Badalona, Catalonia, Spain, whose Clinical Pharmacology Unit led by Dr. Magí Farré has conducted extensive human pharmacology studies on MDMA, 2C-B, and other psychedelics. The hospital's ethics committee approved the Beckley Med Foundation's ayahuasca-assisted therapy trial for complicated grief (NCT06150859), and its research institute (IGTP) lists the therapeutic use of psychedelic substances as an active research area.

The Global Coalition for Adaptive Research (GCAR) is a US non-profit that serves as regulatory sponsor for adaptive platform trials, including GBM AGILE (glioblastoma) and the DOD-backed M-PACT (NCT05422612), which simultaneously evaluates multiple pharmacotherapies for PTSD in active-duty service members and veterans. GCAR modernizes drug development by replacing ineffective arms with new candidates within a single master protocol.

Grand Hôpital de Charleroi (GHdC) is a large multi-site hospital system with six hospitals in Charleroi, Wallonia, Belgium, listed as a clinical research center on the European Clinical Trials Information Network. The hospital sponsors ESKEFIB (NCT04436250), a prospective randomized double-blind trial evaluating S-ketamine as a treatment for fibromyalgia, contributing to Belgium's growing ketamine clinical research infrastructure.

The Hartford HealthCare (HHC) Research Open Competition is an internal pilot grant program run by Hartford HealthCare — a large non-profit integrated health system in Connecticut — to fund investigator-initiated research at its affiliated institutions. Through this program, HHC supports a Phase I double-blind psilocybin microdosing trial at its Olin Neuropsychiatry Research Center in Hartford, investigating effects on cognition, mood and quality of life.

HaEmek Medical Center is a regional public hospital in Afula, northern Israel, affiliated with the Technion's Rappaport Faculty of Medicine and operated by Clalit Health Services, serving 700,000 citizens in the Jezreel Valley. The hospital is a designated site for MAPS Israel's multi-site MDMA-assisted group therapy trial for PTSD and moral injury in veterans, contributing to Israel's pioneering psychedelic-assisted therapy research infrastructure.

Hadassah Medical Organization is a major non-profit academic medical center in Jerusalem, Israel, home to the Hadassah BrainLabs Center for Psychedelic Research, which develops novel psychedelic-based treatments for psychiatric disorders. The organization runs MDMA-assisted psychotherapy trials for PTSD (NCT06954025) and ketamine trials for depression (NCT05026203), and serves as the Phase 1 clinical pharmacology site for Ketamir-2, a novel oral ketamine analog.

Hammersmith Medicines Research (HMR) is the UK's largest Phase 1 clinical research organization, holding MHRA Phase 1 accreditation and a Home Office licence for controlled drug substances including psychedelics. HMR led the Phase I/IIa clinical trial of SPL026 (DMT fumarate) for major depressive disorder on behalf of Small Pharma, positioning it as a leading UK site for early-phase psychedelic medicine trials.

Harvard University hosts multiple psychedelic research initiatives including the Study of Psychedelics in Society and Culture (a $16M program), the MGH Center for the Neuroscience of Psychedelics, and the Harvard Law School POPLAR project addressing psychedelic policy reform. These programs span neuroscience, cultural studies, and legal advocacy to advance scientific and societal understanding of psychedelics.

Helsinki University Hospital (HUS) is Finland's largest academic medical center and the clinical partner of the University of Helsinki's Neuropsychopharmacology and Neuroscience Center laboratories, which produced the landmark discovery that psychedelics directly bind the TrkB BDNF receptor with far greater affinity than conventional antidepressants. As Finland's primary academic hospital, HUS provides the clinical infrastructure for ketamine-based treatments for suicidal depression and the planned translation of Finnish psychedelic neuroscience into human trials.

Henan Provincial People's Hospital is a major 3A-grade hospital in Zhengzhou, China, with over 4,000 beds and a history dating to 1904; it is a key academic medical center affiliated with Zhengzhou University. Its anesthesiology department researches esketamine applications, including a trial on reducing postoperative anxiety and depression in adolescent patients.

The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) is a congressionally chartered non-profit founded in 1983 that manages research contracts and grants for the U.S. Department of Defense across global health, HIV, TBI, and PTSD. HJF is affiliated with clinical research investigating ketamine for sedation in severe traumatic brain injury — a condition at the intersection of military medicine and emerging ketamine-based therapies.

Herzog Hospital is Israel's oldest psychiatric institution (est. 1894), operating 550 beds in Jerusalem and home to the country's only dedicated inpatient unit for severe treatment-resistant depression. Researcher Dr. Uriel Heresco-Levy leads investigation of novel psilocybin combinations with NMDAR modulators for depression, including a joint patent with Hadassah BrainLabs (PCT WO 2024/052895 A1).

Homeostasis Therapeutics LLC is a Delaware company (est. 2020) that developed a novel protocol combining medically supervised ketogenic diet with ketamine infusions for treatment-resistant anorexia nervosa. In 2021–2022 they conducted a five-person IRB-approved pilot study in which four of five participants showed meaningful clinical improvement, advancing the concept of metabolic-state-dependent psychedelic therapy.

Hospital Descentralizado Dr. Marcial V. Quiroga is a public hospital in Rivadavia, San Juan Province, Argentina, serving as a key healthcare facility for the Cuyo region with active research and teaching programs. The hospital is a site for pioneering trials of sublingual 5-MeO-DMT — investigating microdoses for depression and anxiety, and higher doses for anxiety and depression in mild cognitive impairment — among the first Argentine institutions to participate in 5-MeO-DMT clinical research.

Hospital Moinhos de Vento (HMV) is a leading private non-profit hospital in Porto Alegre, Brazil, recognized as one of the country’s top healthcare institutions by national quality rankings. HMV is a reference center for ketamine treatment and co-hosts a naturalistic multicenter study (NCT05249309) with HCPA on subcutaneous ketamine infusions for depressed patients with active suicidal ideation.

Hospital Universitari Sant Joan de Reus is a Catalan university hospital operated by Grup SAGESSA in Reus, Tarragona, with a pioneering harm reduction and substance use disorders program. In 2020, ICEERS partnered with the hospital to conduct the first-ever Phase II clinical trial of ibogaine for opioid-dependent patients on methadone maintenance, making Sant Joan one of Europe’s most historically significant psychedelic research sites.

The Vall d’Hebron Research Institute (VHIR) is the biomedical research arm of Hospital Universitari Vall d’Hebron in Barcelona, one of Spain’s largest tertiary academic medical centers. VHIR researchers are investigating ketamine-assisted psychotherapy for chronic pain comorbid with major depression, exploring both psychedelic-dose intramuscular and psycholytic-dose sublingual approaches.

Hospital de Clínicas de Porto Alegre (HCPA) is a major university hospital affiliated with the Universidade Federal do Rio Grande do Sul (UFRGS) and one of Brazil’s leading academic medical centers. HCPA researchers conduct active ketamine research, including a study of ketamine combined with electroconvulsive therapy for depression and a multicenter trial of subcutaneous ketamine infusions for patients with active suicidal ideation (NCT05249309).

Huazhong University of Science and Technology (HUST) is one of China’s leading research universities in Wuhan, with Tongji Medical College and Union Hospital as major clinical research hubs. HUST researchers have conducted multiple esketamine trials — including studies on esketamine for ICU emergency intubation, postoperative neurocognitive dysfunction in elderly patients, and novel nanocarrier delivery systems to improve ketamine’s antidepressant precision.

HumanKindLabs is a Swedish research organization founded by chemist Ulf Bremberg (Uppsala University) that catalyzes psychedelic clinical research by optimizing therapeutic protocols around set and setting. It co-coordinates PsyPal — the first EU-funded multi-site randomised trial of psilocybin therapy, a €6.5M 19-partner consortium studying psilocybin for psychological distress in palliative care patients with COPD, MS, ALS, and atypical Parkinson’s disease.

Hunan Provincial Maternal and Child Health Care Hospital is a Class-III Grade-A specialist maternity and pediatric hospital in Changsha, Hunan Province, China, founded in 1947 with over 1,050 beds and 10,000 births annually. The hospital’s anesthesiology team is a leader in esketamine obstetrics research, including a landmark BMJ randomised trial (NCT04414943) showing a single low-dose esketamine infusion after childbirth reduced major postpartum depression at 42 days by approximately three-quarters in mothers with prenatal depression.

IESE Business School is a global graduate business school at the University of Navarra, based in Barcelona, that contributes to psychedelic research through the PsyPal consortium. As part of the first EU-funded psychedelic clinical study (€6.5M, 19 partners), IESE hosts design thinking workshops and brings expertise in health economics, organizational implementation, and stakeholder strategy to support the psilocybin palliative care trial.

Icahn School of Medicine at Mount Sinai is a leading US academic medical institution home to the Parsons Research Center for Psychedelic Healing, which runs rigorous clinical trials of MDMA- and psilocybin-assisted therapies for PTSD and trauma in veteran and civilian populations.

Idorsia Pharmaceuticals Ltd. is a Swiss publicly traded biopharmaceutical company (spun out of Actelion in 2017) focused on developing medicines for high-unmet-need conditions, with products including the dual orexin receptor antagonist daridorexant (Quviviq) for insomnia. Idorsia is a participating organization in the U.S. Department of Defense PTSD Adaptive Platform Trial, which evaluates multiple therapeutic interventions — including the intranasal ketamine compound SLS-002 — for veterans with treatment-resistant PTSD.

Imelda Hospital is a Catholic general hospital in Bonheiden, in the Antwerp province of Belgium, offering a full range of acute care and specialist services across approximately 550 beds. The hospital has contributed to clinical research on ketamine for the management of acute brain injury patients.

This stakeholder record appears to be a data parsing artifact where only the corporate suffix 'Inc.' was captured without the full organization name. It is listed as a collaborator in two US psilocybin research trials: a VA-sponsored Phase I/II study on psilocybin for depression in spinal cord injury veterans (NCT07251491) and a group retreat psilocybin therapy trial for cancer patients at Fred Hutch/UW Cancer Consortium (NCT07336238).

The Inner Mongolia Autonomous Region Mental Health Center is a government-affiliated regional psychiatric institution in Hohhot, China, affiliated with the School of Mental Health at Inner Mongolia Medical University. The center has participated in clinical research on esketamine for treating depressive episodes with suicidal ideation in patients with mood disorders.

İnönü University is a Turkish state research university in Malatya, with a medical faculty conducting clinical investigations across anesthesiology, psychiatry, and surgery. The university's departments have studied ketamine in obstetric anesthesia, ketamine augmentation of electroconvulsive therapy for psychiatric conditions, and cardiac safety during ECT.

Insel Gruppe AG operates Inselspital (Bern University Hospital), one of Switzerland's five dedicated centers for psychedelic medicine research and among the largest university hospital groups in Europe. The hospital's psychiatry department runs the HaD-PET neuroimaging study on harmine and DMT, and has published real-world outcomes of LSD- and psilocybin-assisted psychotherapy in routine clinical care.

The Institute for Integration of Medicine & Science (IIMS) at UT Health San Antonio is the institution's NIH-funded Clinical and Translational Science Award hub, supporting multi-disciplinary translational research across South Texas. The institute has been involved in a clinical trial combining esketamine with prolonged exposure therapy for post-traumatic stress disorder.

Instituto Nacional de Canciología de México (INCan) is Mexico's federal national cancer institute in Mexico City, operating as a leading oncology specialty hospital and research center. The institute has participated in a clinical trial examining ketamine versus placebo for treating major depression in patients with advanced cancer.

The Integrative Psychiatry Institute (IPI), co-founded by Will Van Derveer MD and Keith Kurlander, is a leading US psychedelic-assisted therapy training organization that has trained over 2,200 healthcare providers in 300-hour programs covering ketamine, MDMA, and psilocybin. IPI's psilocybin track was among the first approved by the Oregon Health Authority, and the institute collaborates with the Usona Institute and ASKP³ to develop evidence-based curricula.

ICEERS (International Center for Ethnobotanical Education, Research and Service) is a Barcelona-based non-profit founded in 2009, dedicated to the scientific study and social integration of ayahuasca, iboga, and other plant medicines, with UN ECOSOC consultative status. The organization launched the first Phase II clinical trial of ibogaine for opioid dependence in 2020, has co-published over 100 peer-reviewed papers, and provides harm reduction, legal support, and drug policy advocacy globally.

Istanbul Training and Research Hospital is a major public academic medical center in Istanbul, Turkey, affiliated with the Istanbul Provincial Health Directorate and serving as a regional training hub for medical residents and specialists across multiple disciplines. The hospital has conducted clinical research on subanesthetic ketamine doses for postoperative mood improvement in gynecological surgical patients.

Istituto Superiore di Sanità (ISS) is Italy's National Institute of Health, the country's principal technical and scientific public body for biomedical research, public health surveillance, and regulatory advisory functions. The institute has participated in pharmacological research on designer psychoactive substances including methylone, an MDMA analogue, contributing to Italy's evidence base for novel psychoactive substance regulation.

Janssen Korea Ltd. is the South Korean affiliate of Janssen Pharmaceuticals, the pharmaceutical subsidiary of Johnson & Johnson. The company markets esketamine nasal spray (Spravato) in South Korea following regulatory approval for treatment-resistant depression and major depressive disorder with acute suicidal ideation.

Jiangsu HengRui Medicine Co., Ltd. is one of China's largest publicly listed pharmaceutical companies, specializing in innovative drugs across oncology, anesthesia, and metabolic diseases. The company has developed HR071603, a proprietary ketamine nasal spray candidate, which entered Phase I clinical evaluation in healthy subjects.

Johnson & Johnson is an American multinational healthcare corporation and one of the world's largest pharmaceutical companies, operating its pharmaceutical business through the Janssen subsidiary. Through Janssen, J&J developed and commercialized esketamine nasal spray (Spravato), which received FDA approval in 2019 as the first rapid-acting antidepressant approved in decades.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (JJPRD) was the pharmaceutical R&D subsidiary of Johnson & Johnson, subsequently rebranded and integrated into Janssen Research & Development. As a predecessor entity, it conducted foundational early clinical research into esketamine that led to the development of Spravato for treatment-resistant depression.

The Juvenile Bipolar Research Foundation is a US non-profit dedicated to funding scientific research into bipolar disorder in children and adolescents. The foundation has supported clinical research on intranasal ketamine for pediatric bipolar disorder and neurobiological studies of ketamine's effects in children and adults with bipolar disorder.

KGK Science Inc. is a Canadian contract research organization (CRO) based in London, Ontario, specializing in clinical trial execution across natural health products, novel therapeutics, and medical devices. The company has served as a trial management partner on psilocybin studies for treatment-resistant PTSD and behavioral and cognitive symptoms in adults with Fragile X Syndrome.

Karolinska Institutet is Sweden's largest medical university and a leading European hub for psychedelic research, with the Centre for Psychiatry Research led by Prof. Johan Lundberg conducting PSIPET — Sweden's first RCT of psilocybin for major depressive disorder. The institute participates in the Nordic Network for Psychedelic Science and launched a doctoral course in psychedelic science in 2025.

Kernel is a US neurotechnology company founded by Bryan Johnson that develops non-invasive brain measurement devices, including the Kernel Flow (time-domain fNIRS) and Kernel Flux (MEG) systems. The company's neuroimaging technology is used in the PREDICT trial, which investigates brain activity biomarkers for predicting response to depression interventions including ketamine.

Khyber Medical University (KMU) is a public medical research university in Peshawar, Khyber Pakhtunkhwa, Pakistan, operating multiple affiliated teaching hospitals and health sciences colleges across the region. The university's medical faculty has contributed to clinical research on anesthetic and sedative agents including ketamine in perioperative and psychiatric contexts.

One of the longest-operating ketamine therapy networks in the United States, Klarisana runs five intramuscular ketamine clinics across Texas and Colorado—founded in San Antonio in 2015 and a founding member of the American Society of Ketamine Physicians. The practice participated in clinical research on ketamine infusion therapy for PTSD in paramedics, having administered nearly 20,000 IM ketamine sessions annually by 2022.

An atai Life Sciences subsidiary and Columbia University spinout, Kures developed KUR-101—a deuterated mitragynine derivative from the kratom plant—as a safer opioid receptor modulator for acute pain and opioid use disorder, with a second asset KUR-002 targeting depression. The Phase 1 trial of KUR-101 in healthy adults demonstrated safety and tolerability with no severe adverse events, advancing a kratom-derived mechanism distinct from conventional opioids.

A Los Angeles ketamine treatment and functional medicine clinic that pioneered at-home sublingual ketamine microdosing programs, Limbic Medical published research in the Journal of Psychedelic Studies showing 100% improvement in anxiety and 96% improvement in PTSD among frontline healthcare workers treated with daily low-dose sublingual ketamine during the COVID-19 pandemic. The clinic integrates ketamine infusions, hydration therapies, and telemedicine-based microdose programs under its founding physician.

A Seventh-day Adventist university and academic health system in Loma Linda, California with a medical school, research hospital, and multiple health sciences schools; Loma Linda University researchers have investigated the neurophysiological mechanisms of ketamine in the prefrontal cortex and conducted a clinical trial of low-dose ketamine infusion for treatment-resistant depression.

The non-profit research arm of Harbor-UCLA Medical Center in Torrance, California, the Lundquist Institute hosted Dr. Charles Grob's landmark 2004–2008 pilot study—one of the first modern psilocybin trials for anxiety in advanced-stage cancer patients, published in Archives of General Psychiatry (2011). The Institute subsequently received $1.75M from the Steven & Alexandra Cohen Foundation and a Samberg Foundation gift to co-lead a new multi-site psilocybin palliative care trial alongside NYU's Dr. Anthony Bossis.

A leading medical research university in Lviv, western Ukraine, founded in 1784 and one of the oldest medical schools in Eastern Europe; Lviv National Medical University researchers have studied ketamine, stellate ganglion block (SGB), and combination approaches for treating traumatic brain injury (TBI)—research carrying particular relevance given Ukraine’s frontline experience with combat-related neurotrauma.

One of the world’s leading comprehensive cancer centers, affiliated with UT Health Houston, MD Anderson Cancer Center has emerged as a site for landmark psychedelic research; the institution is conducting psilocybin-assisted psychotherapy trials in patients with advanced cancer and co-investigates NeuroGuard—a novel trial exploring psilocybin to prevent chemotherapy-induced peripheral neuropathy.

A full-service UK Contract Research Organisation (CRO) based in Manchester, MAC Clinical Research made history as the first company in the UK to administer high-dose ibogaine in a clinical environment, as well as the first to dose 50mg psilocybin and deuterated DMT. The firm serves as the CRO for DemeRx and atai Life Sciences’ MHRA-approved Phase I/IIa trial of ibogaine HCl (DMX-1002) for opioid use disorder, conducted at their Manchester Early Phase Unit.

The Amsterdam-based European subsidiary of MAPS (Multidisciplinary Association for Psychedelic Studies), MAPS Europe B.V. was established in 2018 to advance MDMA-assisted psychotherapy through EMA-regulated Phase 2 and Phase 3 clinical trials for PTSD across Europe. The organization ran the first multi-site European MDMA/PTSD Phase 2 open-label study with sites in London, Berlin, Lisbon, and others, and trained therapists from 14 countries.

The MIND Foundation is a Berlin-based nonprofit founded in 2016 that advances psychedelic therapy through research, education, and policy advocacy across Europe, supporting clinical trials including the EPIsoDE psilocybin study and the planned DiMension Phase III trial with over 700 patients. It runs the MIND Academy for professional psychedelic training and hosts the biannual INSIGHT conference connecting researchers, clinicians, and the public.

MADoPA (Maintien en Autonomie à Domicile des Personnes Âgées) is a French expert centre and Living Lab founded in 2008 in Troyes, specializing in the co-design and socio-anthropological evaluation of technologies and services supporting elderly and disabled people’s independence at home, affiliated with EIT Health since 2014. As a PsyPal consortium partner, MADoPA leads the Public and Patient Involvement Workgroup (WP4), contributing qualitative research and ethnographic methodologies to the EU-funded €6.5M psilocybin palliative care trial.

Thailand’s highest-ranked research university, comprising 17 faculties including the Faculty of Medicine Siriraj Hospital and Ramathibodi Hospital in Bangkok; Mahidol University researchers have conducted a randomized controlled pilot trial of three consecutive daily IV ketamine infusions for treatment-resistant depression and published multiple studies and reviews on ketamine and esketamine efficacy and safety in major depressive disorder.

Multi-campus academic medical center and one of the most recognized healthcare institutions in the world. Mayo Clinic researchers have published evidence reviews on psilocybin-assisted therapy for depression, anxiety, and alcohol use disorder, and have collaborated on ketamine clinical trials — including a biomarker study with the University of Michigan — for treatment-resistant depression.

A leading Canadian research university in Montreal, Quebec, McGill pioneered the “Montreal Model”—an integrative biomedical-psychedelic approach to ketamine-assisted psychotherapy for severe treatment-resistant depression developed over 6 years and 500+ ketamine treatments. The team’s MUSIK randomized trial demonstrated that emotional and mystical ketamine experiences within a structured therapeutic environment drive more sustained antidepressant improvements, including in ketamine vs. ECT comparison trials.

The Research Institute of McGill University Health Centre (RI-MUHC) is a leading academic health research organization affiliated with McGill University in Montreal, operating across six disease-focused research programs; the centre served as a clinical site for the MusKiP trial—investigating music-enhanced ketamine therapy for chronic pain—and contributes hospital infrastructure and patient populations to the Montreal Model of ketamine-assisted psychotherapy for treatment-resistant depression.

A Canadian research university in Hamilton, Ontario, McMaster University houses the Centre for Medicinal Cannabis Research and an expanding psychedelic science program including the McMaster Psychedelic Research Society; the university is sponsoring the PSI_CUD trial—a Phase 2 proof-of-concept study of psilocybin-assisted psychotherapy (two 25mg doses within an 8-week Motivational Enhancement Therapy framework) for cannabis use disorder.

Harvard Medical School-affiliated psychiatric hospital and one of the leading mental health research institutions in the United States. Operates a dedicated Ketamine Service for treatment-resistant depression and is actively expanding into psilocybin research for depression, bipolar disorder, and other psychiatric conditions.

Leading Austrian medical university in Innsbruck. Researchers here have investigated the structural biology of psilocybin-biosynthesizing enzymes with the aim of optimizing sustainable psilocybin production, while also contributing to clinical research as European psychedelic frameworks evolve.

The Medical University of Gdańsk is Poland's leading academic medical institution, with its Department of Psychiatry running one of the country's most active research programs on ketamine and esketamine for treatment-resistant depression and bipolar disorder.

Melt Pharmaceuticals is a US specialty pharmaceutical company — carved out from Harrow, Inc. in 2019 and subsequently re-acquired — that developed MELT-300, a sublingual fast-dissolving tablet combining ketamine (50 mg) and midazolam (3 mg) for opioid-free procedural sedation using Catalent's Zydis® technology. The company reported positive Phase 3 topline results for cataract surgery sedation in November 2024, positioning MELT-300 for FDA regulatory submission.

MercyOne Des Moines Medical Center is a 622-bed hospital in Des Moines, Iowa, certified as a Level II Area Trauma Care Facility and part of the Trinity Health system. The center served as the primary site for a clinical study of antidepressant ketamine administered in the emergency department for patients presenting with severe depression or suicidal ideation (NCT04266288), and subsequently integrated Spravato (esketamine) nasal spray into its behavioral health services.

Home to the Michigan Psychedelic Center (M-PsyC), a multidisciplinary initiative launched in 2022 by the University of Michigan to advance psychedelic science with rigor and responsibility. M-PsyC conducts clinical trials on psilocybin for fibromyalgia and depression, and DMT research, spanning neuroscience, psychiatry, pharmacology, and nursing.

Mike O'Callaghan Military Medical Center is the primary military hospital at Nellis Air Force Base in Las Vegas, Nevada, operated by the 99th Medical Group and serving active duty personnel and their families through TRICARE. The center sponsored the CHECK Trial — a multicenter, randomized, double-blind study comparing sub-dissociative ketamine against prochlorperazine for emergency department headache treatment, published in Annals of Emergency Medicine in 2018.

NHS Grampian is the National Health Service health board serving northeast Scotland — including the city of Aberdeen and surrounding Aberdeenshire — providing acute hospital care through facilities such as Royal Cornhill Hospital and Aberdeen Royal Infirmary. The organisation led the KANECT randomised controlled trial comparing ketamine against propofol as ECT anaesthetic for major depression, conducted at Royal Cornhill Hospital between 2011 and 2013 and published in the British Journal of Psychiatry in 2017.

NWTraumatherapies is a Bozeman, Montana-based network organisation directed by mechanotherapist Ross Allison that developed the Northwest Therapies Trauma Psilocybin Study (NWTTPS), a compassionate use protocol exploring enhanced psilocybin microdosing for chronic trauma conditions including PTSD, depression, and long COVID. The study (NCT05042466) lists Imperial College London, the WHO, and Johns Hopkins University as scientific collaborators and employs a multi-week microdosing protocol with therapist-supervised integration.

Home to the NYU Langone Center for Psychedelic Medicine, one of the world's leading academic institutions in psychedelic research. Has conducted landmark psilocybin trials for smoking cessation, alcohol use disorder, and depression in cancer patients, spearheaded by Dr. Michael Bogenschutz and colleagues.

Nanfang Hospital (南方医院) is a Grade-A tertiary hospital affiliated with Southern Medical University, founded in 1941 in Guangzhou, China, with 3,601 beds and over 3.25 million outpatient visits annually, consistently ranked among China’s top 20 hospitals by Fudan University. The hospital’s Department of Anesthesiology has investigated the effects of low-dose esketamine on postoperative delirium prevention in high-risk elderly surgical patients in the ELEMENT trial, contributing to a growing body of Chinese RCT evidence on esketamine’s neuroprotective properties.

The National Center for PTSD (NC-PTSD) is a US Department of Veterans Affairs centre of excellence for research, education, and training on post-traumatic stress disorder, operating across seven VA medical centre sites with a focus on evidence-based assessment and treatment. The Centre has supported mechanistic ketamine research in military and veteran populations, including an investigation of AMPA receptor blockade on ketamine’s anti-suicidal effects relevant to veteran mental health crises.

The National Institute of Neurology and Neurosurgery (INNN; Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez) is a Mexican federal specialist hospital and research institute in Mexico City dedicated to the diagnosis, treatment, and study of neurological and neurosurgical conditions. The INNN has been a centre for ketamine research in treatment-resistant depression, conducting trials evaluating intravenous ketamine dosing regimens for patients unresponsive to standard antidepressant therapy.

The National Network of Depression Centers (NNDC) is a US non-profit consortium of academic medical centres united to advance the prevention, diagnosis, and treatment of mood disorders through collaborative research, clinical programmes, and policy advocacy, with member institutions spanning more than 25 major academic health systems. The NNDC supported the BIO-K study, an open-label biomarker development trial investigating intravenous ketamine for non-psychotic unipolar major depression and bipolar I/II depression.

The National University of Natural Medicine (NUNM) is a Portland, Oregon-based accredited institution offering graduate programmes in naturopathic medicine, integrative medicine, and classical Chinese medicine, with a research focus on evidence-based natural health approaches. NUNM co-sponsored the Optimizing Microdosing and Meditation (OMM) trial, studying whether combining psilocybin microdosing with structured mindfulness meditation practice produces synergistic improvements in psychological wellbeing.

The National and Kapodistrian University of Athens (NKUA; Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών) is Greece’s oldest and largest university, founded in 1837, with one of Southern Europe’s largest medical schools conducting both basic science and clinical research. NKUA researchers have investigated the co-administration of lidocaine and ketamine as an analgesic protocol for opioid-refractory chronic cancer-related pain, exploring combination approaches as alternatives to escalating opioid therapy.

Nationwide Children's Hospital is a leading pediatric academic medical center in Columbus, Ohio, operating one of the largest sickle cell disease programs in the state and providing comprehensive care for pediatric hematology, psychiatry, and pain management. The hospital has conducted research on IV ketamine as an adjunct for sickle cell vaso-occlusive pain crises and suicidal ideation in adolescents.

Naval Medical Center Camp Lejeune is the primary U.S. military hospital serving Marine Corps Base Camp Lejeune in Jacksonville, North Carolina, operating ACGME-accredited residency programs in family medicine and psychiatry. The center sponsored NCT04260607, a randomized controlled trial of IV ketamine versus placebo for rapid stabilization of acutely suicidal patients presenting to the emergency department.

NRx Pharmaceuticals (formerly NeuroRx, Nasdaq: NRXP) is a clinical-stage biopharmaceutical company developing a sequential therapy for suicidal bipolar depression: NRX-100 (preservative-free IV ketamine) for acute stabilization followed by NRX-101 (D-cycloserine/lurasidone) for maintenance, both holding FDA Breakthrough Therapy Designation. The company filed an NDA with the FDA for NRX-100 in 2024 in support of accelerated approval.

Neurological Associates of West Los Angeles (NAOWLA) is a private neurology and psychiatry group practice in Santa Monica, California, founded in 1981 and affiliated with the UCLA Department of Neurology. The practice sponsored NCT04205890, a clinical trial investigating intravenous ketamine effects on functional neuroanatomy in treatment-resistant depression via pre/post brain imaging.

State-funded psychiatric research institute affiliated with Columbia University, located in New York City. A key site for psilocybin clinical trials including the landmark COMP360 study for treatment-resistant depression, and conducts broader research on LSD, DMT, ayahuasca, and ketamine through Columbia's Depression Evaluation Service.

Northwell Health is New York's largest health system with 28 hospitals, which opened the Center for Psychedelics Research and Treatment (CPRT) at Zucker Hillside Hospital in 2026 to study psilocybin for anxiety disorders, MDMA for schizophrenia negative symptoms, and ketamine for treatment-resistant depression. The center's Feinstein Family Human Neuropsychopharmacology Laboratory is one of only a handful of US facilities licensed to dispense federal Schedule I substances for research.

Northwestern University's Feinberg School of Medicine Department of Psychiatry & Behavioral Sciences conducts ketamine research including trials for TBI-associated symptoms and perioperative depression, and has begun preclinical psilocybin studies examining psychedelic and psychotomimetic mechanisms. The department also offers clinical trials in schizophrenia, bipolar disorder, depression, and anxiety, with the Osher Center for Integrative Health incorporating psychedelic-assisted therapy education.

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that has advanced MIJ821 — a selective GluN2B/NR2B NMDA receptor antagonist — through a Phase 2 proof-of-concept trial for treatment-resistant depression, exploring the same ketamine-like NMDA antagonism pathway. MIJ821's rapid-acting antidepressant mechanism is part of Novartis's broader CNS drug discovery pipeline.

Ontario Shores Centre for Mental Health Sciences is a specialized mental health facility in Whitby, Ontario affiliated with the University of Toronto Department of Psychiatry, offering investigational ketamine infusion therapy for treatment-resistant depression. The centre has conducted trials comparing ketamine to ECT and combining IV ketamine with internet-based CBT (Ket-CBT) for suicidality in TRD, and holds the world's first Level 7 EMR maturity validation for a mental health facility.

Oregon Research Institute's Center for Evaluation Services (ORI CES) is a 501(c)(3) non-profit research unit based in Eugene, Oregon that provided methodological and evaluation support to the SAMATI (Social Anxiety MDMA-Assisted Therapy Investigation) trial — an investigator-initiated study by Portland Psychotherapy exploring MDMA-assisted therapy for generalized social anxiety disorder, with study drug supplied by MAPS PBC.

The Ottawa Hospital Research Institute (OHRI) is the research arm of The Ottawa Hospital and affiliated with the University of Ottawa, conducting clinical and translational research spanning 16 departments and over 1,700 scientists and trainees. OHRI has contributed to psilocybin research for psychological and existential distress in palliative care, part of Canada's expanding academic psychedelic medicine research.

PPD Development (now part of Thermo Fisher Scientific's clinical research business) is one of the world's largest contract research organizations (CROs), providing trial management and bioanalytical services for clinical programs including DoD-sponsored studies on SLS-002 (intranasal racemic ketamine) for PTSD in military personnel and veterans through the M-PACT adaptive platform trial.

Parc de Salut Mar is a public hospital consortium in Barcelona, Spain, whose research arm IMIM (Hospital del Mar Medical Research Institute) has conducted controlled human pharmacology studies of MDMA and novel psychoactive substances. Their Integrative Pharmacology and Systems Neuroscience Research Group ran landmark double-blind crossover trials comparing mephedrone to MDMA in healthy volunteers and investigating MDMA pharmacokinetics by sex and CYP2D6 genotype.

Leading academic hospital in Beijing affiliated with Peking University. Has conducted ketamine clinical trials including a randomized study of low-dose ketamine for perinatal depression, contributing to China's growing body of research on rapid-acting antidepressant therapies.

Perception Neuroscience is a New York–based biopharmaceutical subsidiary of atai Life Sciences developing PCN-101 (arketamine, R-ketamine) as a potentially safer, lower-dissociation alternative to racemic ketamine for treatment-resistant depression. The company completed a Phase 1 single-ascending-dose study in 58 healthy volunteers and a Phase 2a double-blind, placebo-controlled trial in TRD patients, with a collaboration with Otsuka Pharmaceutical for the Japanese market.

The Peter Boris Centre for Addictions Research (PBCAR) is a joint addiction research centre of McMaster University and St. Joseph's Healthcare Hamilton in Canada, directed by Dr. James MacKillop. PBCAR is conducting a Phase 2 clinical trial of psilocybin-assisted psychotherapy — two 25 mg psilocybin sessions combined with an 8-week Motivational Enhancement Therapy program — for cannabis use disorder.

Pfizer is a multinational pharmaceutical corporation that, through Pfizer Canada and the Canadian Pain Society, co-funded the KetHead multi-center Phase 3 RCT (NCT05306899) evaluating high-dose IV ketamine for chronic daily headaches at Toronto Western Hospital and Sinai Health System. The trial targets NMDA receptor-mediated central sensitization underlying refractory headache disorders.

The Pharmaceutical Research Unit (PRU) is the first contract research organization established in Jordan (1993), headquartered in Amman and accredited by the US FDA, EU authorities, and multiple MENA health agencies. PRU served as the clinical site and collaborating organization for Lobe Sciences' Phase 1 first-in-man pharmacokinetic study of psilocin mucate (L-130), a stabilized psilocin salt with near-100% bioavailability investigated as a low-dose at-home therapeutic.

Pontificia Universidad Catholica de Chile (UC Chile) is one of Chile's most prestigious research universities, whose Division of Anesthesiology in Santiago has conducted ketamine pharmacokinetic/pharmacodynamic research including the Keta-ANI study, which characterized the temporal antinociceptive profile of IV ketamine bolus using the Analgesia Nociception Index and developed an effect-site TCI model for analgesic dosing.

Portland Psychotherapy is a Portland, Oregon clinic, research, and training center that integrates psychedelic science into evidence-based clinical practice, conducting clinical trials of MDMA-assisted therapy for social anxiety disorder and offering psychedelic integration services. Their distinctive model funds peer-reviewed research through clinical revenue, resulting in exceptionally well-trained therapists in psychedelic-assisted care.

Portland Psychotherapy Clinic, Research, and Training Center is a Portland, Oregon social enterprise where clinical practice funds scientific research on psychedelic-assisted therapy, co-founded in 2007 by Dr. Jason Luoma and Dr. Jenna LeJeune. The center sponsors the SAMATI trial (MDMA-assisted therapy for social anxiety disorder) and a pilot study of psilocybin for chronic pelvic pain in women, in partnership with Oregon Research Institute Center for Evaluation Services and with MAPS PBC providing study drug.

The Portland VA Research Foundation, Inc. is a non-profit entity supporting clinical research at the Portland VA Health Care System in Oregon. It sponsors the SNaP Lab's psilocybin-enhanced psychotherapy trial for methamphetamine use disorder (with the Cohen Foundation) and the Group-MVP MDMA group therapy trial for Veterans with PTSD, both led by Dr. Christopher Stauffer, an OHSU Associate Professor of Psychiatry.

The Section of Psychiatry at the University of the West Indies (UWI) Mona, led by Professor Roger Gibson within the Faculty of Medical Sciences' Department of Community Health and Psychiatry, is conducting a clinical trial assessing the efficacy of microdosed psilocybin on reducing anxiety and depression levels in adults in Jamaica.

Providence Care Hospital in Kingston, Ontario hosts Canada's first hospital-based psychedelic research centre — the Centre for Psychedelics Health and Research (opened 2024) — in partnership with Queen's University and CAN-BIND, conducting psilocybin and LSD research alongside its established IV ketamine clinic for treatment-resistant depression led by Dr. Claudio Soares.

Psilo Scientific Ltd is a Health Canada-licensed psilocybin producer and wholly-owned subsidiary of Filament Health Corp (NEO: FH), supplying purified botanical psilocybin (PEX010) to clinical trials including the PSYCHED-PAL palliative care microdosing study; it also licensed PEX010 to Cybin for Phase 2 trials in treatment-resistant depression and alcohol use disorder.

The Psychedelic Data Society is a US-based citizen-science nonprofit managing the Psychedelic Data Project, a global harm reduction and research initiative that collects participant-contributed data to accelerate psychedelic science and inform evidence-based drug policy reform.

The Psychiatric University Hospital Zurich (PUK) is affiliated with the University of Zurich and home to Franz Vollenweider's pioneering psychedelic neuroscience group, active since the 1990s; research includes PET imaging with psilocybin, S- and R-ketamine, MDMA, and DMT+harmine formulations, including a completed 2023 RCT of psilocybin (0.215 mg/kg) vs. placebo for major depressive disorder.

Psyence Australia Pty Ltd is the Australian subsidiary of Psyence Biomed Ltd (Nasdaq: PBM), a company focused on nature-derived botanical psilocybin medicine; it received HREC approval to conduct a Phase IIb randomized double-blind trial evaluating natural psilocybin (NPX-5 at 10 mg and 25 mg) versus an active low-dose comparator for adjustment disorder in palliative care cancer patients, with sites in Melbourne and Perth.

Psyrin Inc. is a UK-based AI health startup founded by researchers from King's College London that develops speech analysis algorithms using machine learning to rapidly assess serious mental illness from brief voice recordings; its patent-pending technology achieved 86% accuracy distinguishing psychosis-spectrum disorders from other conditions in a Translational Psychiatry publication, and is being studied as a tool for predicting treatment response to psychiatric interventions.

Qinghai Red Cross Hospital (青海红十字医院) is a JCI-accredited 3A-grade comprehensive hospital with 2,000 beds in Xining, Qinghai Province, China, established in 1949 and the first hospital in western China to receive JCI accreditation; affiliated researchers are participating in clinical trials investigating intraoperative esketamine as a preventive treatment for postpartum depression following cesarean section.

Qinghai University (青海大学) is a public comprehensive research university in Xining, Qinghai Province, China; its affiliated hospital and medical faculty are involved in clinical research investigating intraoperative esketamine as a preventive treatment for postpartum depression in women undergoing cesarean section.

Quantified Citizen Technologies Inc. is a Canadian privacy-centric mobile health research platform powering decentralized citizen-science studies; it built the world's first mobile app for psychedelic microdosing data collection (Microdose.me) with over 19,000 participants worldwide, whose findings were published in Nature Scientific Reports, and continues to host multiple psychedelic observational studies in partnership with MAPS, UBC, and researchers including Paul Stamets and James Fadiman.

RIVER Foundation is a US-based nonprofit conducting observational research on ketamine treatment plans for chronic conditions, including an ongoing study led by a doctoral candidate in clinical psychology; through its Assimilation Program, it connects patients with licensed physicians who can prescribe home-based ketamine sessions with integration support.

Rady Children's Hospital San Diego is a leading US pediatric academic medical center with over 200 active clinical trials; its emergency department research team is studying whether a single low-dose IV ketamine infusion reduces depression symptoms and suicidal ideation in adolescents compared to placebo, aiming to expand rapid treatment options in the emergency setting.

Region Orebro County is a Swedish regional public health authority in central Sweden whose University Hospital (Universitetssjukhuset Orebro) is a participating site in the CAPSI trial, a randomized study investigating single-dose psilocybin-assisted psychotherapy for major depression in adult cancer patients.

Remedy is a Toronto-based mental health innovation community founded by Dr. Anne Wagner, C.Psych., that conducts psychedelic research through its Remedy Institute arm; Dr. Wagner leads two MDMA-assisted psychotherapy trials for PTSD — a pilot open-label study combining MDMA with Cognitive Processing Therapy (CPT), and a randomized controlled trial combining MDMA with Cognitive Behavioral Conjoint Therapy (CBCT), a couples therapy approach.

The Rett Syndrome Research Trust (RSRT) is a US-based nonprofit dedicated to curing Rett syndrome (RTT) that funded, held the IND for, and oversaw a randomized double-blind placebo-controlled crossover trial of oral ketamine in girls aged 6-12 with RTT; the study confirmed safety and tolerability and demonstrated EEG evidence of NMDA receptor target engagement, supporting further trials with longer duration or higher doses.

Copenhagen University Hospital Rigshospitalet is Denmark's foremost academic medical center, home to the Neurobiology Research Unit (NRU) led by Professor Gitte Moos Knudsen, which has conducted psychedelic neuroimaging research with psilocybin and LSD since 2017; its affiliated NOESIS clinical research unit runs active trials investigating psilocybin for depression, OCD, and cancer-related distress, plus LSD serotonin 2A receptor occupancy imaging studies, in collaboration with Imperial College London and Karolinska Institutet.

Rose Hill Life Sciences is a North American psychedelic life sciences company that supplies research-grade Psilocybe cubensis biomass and sponsors clinical trials, including the PHATHOM study testing psilocybin combined with physical therapy to restore motor function in stroke patients; it also collaborates with Johns Hopkins, the University of Guelph, and the Canadian Centre for Psychedelic Science, and has operated a psilocybin mushroom cultivation facility since 2015.

Roswell Park Comprehensive Cancer Center in Buffalo, NY operates a Psychedelic Science Initiative (PSI) conducting research on psilocybin and ketamine for cancer patients; active trials include an open-label psilocybin microdosing study for chronic cancer pain and opioid reduction, a Phase 2 trial of the novel psychedelic RE104 for adjustment disorder in cancer patients, and a palliative esketamine clinic for co-morbid treatment-resistant depression.

Royal North Shore Hospital (RNSH) in St Leonards, New South Wales, Australia is a major academic medical center within the Northern Sydney Local Health District; its CADE Clinic (Department of Psychiatry) and Northern Sydney Anaesthetic Research Institute have participated in multiple ketamine trials including the KADS Phase 3 RCT of subcutaneous racemic ketamine for treatment-resistant depression, and real-world esketamine studies for depression management.

The Royal University Hospital Foundation is the charitable fundraising arm of Royal University Hospital in Saskatoon, Saskatchewan, which has invested over $194 million into research, education, and patient care at Saskatchewan's largest academic hospital; the Foundation has supported psychiatry research including ECT and ketamine anesthesia comparative trials and Dr. Evyn Peters' groundbreaking work using intranasal racemic ketamine for hospitalized patients with treatment-resistant depression.

The Quebec Network on Suicide, Mood Disorders and Associated Disorders (RQSHA) is a publicly-funded interdisciplinary research network supported by the Fonds de recherche du Québec that brings together researchers from across Quebec to study suicide, mood disorders, and substance use; it has funded several ketamine trials including the 'Montreal Model' study integrating psychedelic-informed ketamine therapy with psychological support for severe treatment-resistant depression, and research on music as an intervention to improve ketamine tolerability in depression treatment.

Salem Anaesthesia Pain Clinic is an outpatient anesthesia and pain management clinic in Surrey, British Columbia, led by Dr. Olu Bamgbade, a clinical assistant professor with over 25 years of experience in the UK, USA, and Canada; the clinic offers IV ketamine infusion for treatment-resistant depression, mood disorders, and chronic pain, and has conducted clinical research demonstrating that ketamine enhances both analgesia and mood outcomes in chronic pain patients.

The San Francisco Department of Public Health is the public health agency of the City and County of San Francisco, operating clinics, HIV/AIDS programs, and behavioral health services for over 125,000 patients annually; through its Behavioral Health Services division, it is conducting the KARE (Ketamine-Assisted Recovery) trial investigating ketamine-assisted psychotherapy for methamphetamine use disorder in publicly-insured adults with or at risk for HIV, integrating harm reduction principles with neuroplasticity-based addiction treatment.

The Saskatoon Health Region (now integrated into the Saskatchewan Health Authority) was the regional health authority responsible for hospital and community health services in Saskatoon and surrounding areas in Saskatchewan, Canada; through Royal University Hospital, it supported pioneering ketamine research for psychiatric conditions including comparative ECT and ketamine anesthesia trials, and the intranasal racemic ketamine protocol for hospitalized patients with treatment-resistant depression developed by Dr. Evyn Peters.

The Section for Affective Disorders at Norra Stockholms Psykiatri (Northern Stockholm Psychiatry) is a specialist psychiatric unit within Region Stockholm, Sweden, led by Associate Professor Johan Lundberg of Karolinska Institutet; it sponsors two active psilocybin trials — the CAPSI randomized trial investigating a single oral dose of psilocybin 25 mg for cancer-related major depressive disorder in 100 patients, and the PSIPET Phase 2b PET imaging study measuring psilocybin's effect on synaptic density as a biomarker for MDD treatment response.

Shalvata Mental Health Center is a 114-bed comprehensive psychiatric hospital founded in 1956 in Hod HaSharon, Israel, affiliated with Clalit Health Services and the Sackler Faculty of Medicine at Tel Aviv University; it is one of Israel's most active psychedelic research sites, having conducted trials comparing intranasal versus intravenous ketamine administration, MDMA-assisted psychotherapy for borderline personality disorder, and ketamine combined with cognitive behavioral analysis system of psychotherapy (CBASP) for chronic treatment-resistant depression.

Israel's largest hospital and a major academic medical center affiliated with Tel Aviv University. A key site for MDMA-assisted psychotherapy trials through MAPS Israel and other research programs, as well as ketamine studies for treatment-resistant depression.

Shenox Pharmaceuticals LLC is a US-based specialty pharmaceutical company developing innovative transdermal delivery systems for psychiatric medications; their lead program SHX-001 is a ketamine transdermal patch that delivers sustained, controlled ketamine plasma concentrations for up to 7 days to treat major depressive disorder while minimizing the adverse effects, abuse potential, and clinic-visit burden of IV and intranasal ketamine, with FDA IND approval granted in 2018 and an ongoing Phase 1 pharmacokinetics and antidepressant efficacy trial.

Sheppard Pratt Health System is a leading non-profit psychiatric hospital and health system in Towson, Maryland, home to the Center of Excellence for Psilocybin Research and Treatment — the first international center of its kind — established in partnership with COMPASS Pathways; it has conducted landmark psilocybin trials including the first trial for bipolar type II depression (published in JAMA Psychiatry with 80% remission at 12 weeks), psilocybin for treatment-resistant depression (published in NEJM), and psilocybin for TRD with chronic suicidal ideation.

Small Pharma Ltd was a UK-based psychedelic biotechnology company that conducted the world's first clinical trials of DMT-assisted therapy for major depressive disorder; their lead compound SPL026 (N,N-dimethyltryptamine fumarate) delivered a short-lived ~20-minute psychedelic experience via IV or IM administration, and the Phase I/IIa program in collaboration with Imperial College London's Centre for Psychedelic Research demonstrated consistent quality of psychedelic response and antidepressant effects; the company was subsequently acquired by Cybin Inc. to create the industry's largest deuterated DMT program.

Soterix Medical is a US-based medical device company specializing in non-invasive neuromodulation technology, primarily transcranial direct current stimulation (tDCS); the company develops tDCS devices used in clinical research trials for treatment-resistant depression, bipolar depression, and substance use disorders, and has contributed to ketamine biomarker validation research exploring how neuromodulation biomarkers can predict or complement ketamine treatment response in patients with major depressive disorder.

South London and Maudsley NHS Foundation Trust (SLaM) is the UK's leading academic mental health Trust, home to Maudsley Hospital and the NIHR Maudsley Biomedical Research Centre; in partnership with COMPASS Pathways and King's College London's Institute of Psychiatry, it has established a dedicated Psychedelics and Mental Health Research Centre conducting psilocybin Phase 3 trials for treatment-resistant depression, MDMA therapy for PTSD, 5-MeO-DMT studies, and the SIGNATURE synaptic imaging biomarker trial, aiming to treat 650–700 patients over five years.

South West Sydney Local Health District (SWSLHD) is a large public health network serving south-west Sydney, New South Wales, Australia; it has participated in cutting-edge psychedelic research trials including KET-DUAL, a pilot study of ketamine-enhanced therapy for patients with co-occurring alcohol use disorder and depression, and MPATHY, an RCT of MDMA-assisted prolonged exposure therapy for comorbid alcohol use disorder and post-traumatic stress disorder.

Spaulding Rehabilitation Hospital is a leading rehabilitation hospital in Boston, Massachusetts, affiliated with the Mass General Brigham health system and home to the Scott Schoen and Nancy Adams Discovery Center for Chronic Pain Recovery. It is pioneering psychedelic research in pain medicine through the first clinical trial of MDMA-assisted therapy for fibromyalgia, which uses hyperscan neuroimaging to investigate how MDMA influences brain-to-brain dynamics between patient and therapist to produce analgesia, in collaboration with PharmAla Biotech.

The Special Operations Care Fund (SOC-F) is a US non-profit organization based in Atlanta, Georgia, that provides direct support to active and retired members of the Special Operations Forces community and their families. It is the sponsor of the Trifecta Research Study — conducted with Johns Hopkins Center for Psychedelic and Consciousness Research — which investigates hormone replacement therapy, magnetic e-resonance therapy (MeRT), ibogaine, and 5-MeO-DMT in combination for the treatment of PTSD and TBI-related cognitive impairment in SOF veterans.

Spital Uster AG is a community hospital in Uster, Switzerland, whose Department of Medicine is affiliated with palliative care physician Sivan Schipper — a member of the Swiss Medical Society for Psycholytic Therapies (SÄPT). Schipper co-authored the landmark Cochrane systematic review of psychedelic-assisted therapy for anxiety, depression, and existential distress in patients with life-threatening diseases, and Spital Uster is associated with Switzerland's LSD-in-palliative-care research program investigating LSD-assisted therapy for anxiety in patients with life-threatening illness.

St Patrick's Mental Health Services (SPMHS) is Ireland's largest independent not-for-profit mental health hospital, located in Dublin, and a leading centre for ketamine research in Ireland. In collaboration with Trinity College Dublin's Professor Declan McLoughlin, it has run the KITE-Dep study (ketamine interleaved with ECT), the KARMA-Dep pilot RCT, and the definitive KARMA-Dep-2 randomised clinical trial — the most rigorous investigation of repeated IV ketamine infusions as adjunctive inpatient therapy for major depression conducted in Ireland.

St. Joseph's Healthcare Hamilton (SJHH) is a multi-site academic health sciences centre in Hamilton, Ontario, Canada, home to the new Centre for Health Innovation and Research in Psychedelics — one of Canada's first dedicated psychedelic research centres. It serves as a test site for the PSYCHED-PAL trial investigating psilocybin microdosing for psychological and existential distress in palliative care patients, and is also conducting trials of psilocybin for cannabis use disorder and chronic pain, with plans to study ketamine, MDMA, and DMT across a broad range of therapeutic indications.

Stella (originally Stella Center, now Stella Mental Health) is a US-based psychiatric practice specializing in interventional psychiatry for PTSD, depression, and anxiety, with a particular focus on military veterans and Special Operations Forces personnel. The organization pioneered the Dual Sympathetic Reset (DSR) — an advanced stellate ganglion block (SGB) protocol — alongside ketamine therapy and Spravato, and is involved in the Reversal of Battle-Related Aging (ROBRA) study investigating interventional approaches to combat-related neurological decline in Special Operations Forces cohorts.

Stockholm University is a major public research university in Stockholm, Sweden, known for its strong departments in psychology, neuroscience, and the social sciences. It is one of 19 European partner institutions in PsyPal — the first EU-funded multicenter randomised controlled trial of psilocybin-assisted therapy for psychological distress in palliative care patients with progressive incurable illnesses including COPD, multiple sclerosis, ALS, and atypical Parkinson's disease, awarded over €6.5 million in Horizon Europe funding.

Major academic hospital in Toronto affiliated with the University of Toronto. Contributes to Canadian psychedelic research through its Odette Cancer Centre's involvement in psilocybin trials for cancer-related distress, and its Department of Psychiatry's participation in CANMAT task forces on psychedelic treatments for depression.

Sunstone Medical (operating as Sunstone Therapies) is a US-based clinical-stage organization headquartered in Rockville, Maryland, that focuses on developing and delivering psychedelic-assisted therapy in the medical setting at its purpose-built Bill Richards Center for Healing at Adventist HealthCare Shady Grove Medical Center. It runs trials of psilocybin for major depression in adults with cancer (in collaboration with COMPASS Pathways and Johns Hopkins), MDMA-assisted therapy for adjustment disorder in cancer patient-caregiver dyads, and psilocybin for sexual assault-related PTSD (SUN004).

Swiss medical society founded in 1985 whose members received special permission from the Swiss Federal Office of Public Health to conduct psychedelic-assisted therapy with MDMA and LSD in private practices from 1988 to 1993, treating approximately 170 patients. SÄPT continues to advance psycholytic therapy through research, training, and individual treatment licenses, and sponsored the LSD-Assist Study demonstrating persistent anxiety reductions at two-year follow-up.

The University of Sydney is Australia's oldest university, founded in 1850, with internationally recognized research programs in medicine, pharmacy, and addiction medicine. Its Faculty of Medicine and Health contributes to cutting-edge ketamine research, including as a collaborating institution in the KET-DUAL pilot study — investigating ketamine-enhanced therapy for individuals with co-occurring alcohol use disorder and depression — conducted through the Drug Health Services at Royal Prince Alfred Hospital in Sydney.

Taipei Veterans General Hospital (TVGH) is a prestigious tertiary-care academic hospital in Taipei, Taiwan, and home to the Precision Depression Intervention Center (PreDIC) — one of Asia's leading centers for ketamine and esketamine treatment of depression. TVGH has conducted pioneering studies of dose-related adjunctive ketamine for genotyped Taiwanese patients with treatment-resistant depression, low-dose ketamine for TRD with prominent suicidal ideation, and low-dose ketamine infusion for adolescents with treatment-resistant depression.

Academic medical center in Northeast Texas and part of The University of Texas System. Conducts clinical research across pulmonary medicine, trauma, cardiology, and neurology, and has participated in trials exploring psychedelic and ketamine-assisted therapies.

Toronto-based health system anchored by St. Michael's Hospital and St. Joseph's Health Centre. The Pinnacle Research Group at St. Michael's is running first-of-its-kind MDMA, ketamine, and psilocybin trials for chronic neuropathic pain, establishing Unity Health Toronto as a leading Canadian centre for psychedelic research.

The University of Groningen's medical center (UMCG) is a leading European hub for psychedelic research, coordinating the EU-funded €6.5M PsyPal clinical trial studying psilocybin for psychological distress in palliative care patients. UMCG also hosts an annual interdisciplinary summer school in psychedelic research in collaboration with the OPEN Foundation and partner universities.

Toronto's largest research hospital network and home to the Nikean Psychedelic Psychotherapy Research Centre — Canada's first dedicated psychedelic research centre, funded by a $5 million donation. Led by Dr. Emma Hapke, UHN's centre conducts psilocybin-assisted therapy trials for cancer patients and body dysmorphic disorder, alongside MDMA research for PTSD.

University hospital affiliated with the University of Bonn and one of Europe's leading academic medical centers. Its psychiatry and neuroscience departments have contributed to research on psychedelic-assisted therapies and novel treatments for mood and anxiety disorders.

Major research university and academic medical center in Birmingham, Alabama. A key site in the first federally funded psilocybin trial in 50 years — a NIH/NIDA-funded multisite study on psilocybin for smoking cessation led by Dr. Peter Hendricks, alongside Johns Hopkins and NYU.

The University of Amsterdam (UvA) is one of the Netherlands' leading research universities, with its Amsterdam UMC Department of Psychiatry conducting clinical trials on psilocybin and psychedelic-assisted therapies for treatment-resistant mental health conditions.

Pioneer in modern American psychedelic research through Rick Strassman's DMT and psilocybin studies in the 1990s — among the first human psychedelic research since the 1970s. Today, UNM Health Sciences conducts active trials of psilocybin, MDMA, and ketamine for depression, PTSD, alcohol use disorder, and methamphetamine addiction.

The Penn Psychedelics Collaborative at the University of Pennsylvania is a multi-school consortium of researchers, clinicians, and faculty advancing transdisciplinary psychedelic science across Penn Medicine and Penn Nursing, including clinical trials of MDMA-assisted therapy and psilocybin research. Penn researchers are also leading the development of bioethical guidelines for psychedelic-assisted therapy and community implementation frameworks.

atai Life Sciences (operating as atai Therapeutics, Inc. in the US) is a publicly traded clinical-stage biopharmaceutical company founded in 2018 with the largest and most diverse portfolio of psychedelic-derived drug candidates, including DMT, R-MDMA, psilocin, 5-MeO-DMT (BPL-003), and ibogaine for depression, anxiety, and addiction. Following its 2024 merger with Beckley Psytech to form AtaiBeckley, BPL-003 received FDA Breakthrough Therapy designation for treatment-resistant depression with Phase 3 trials anticipated in 2026.